Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR

NCT06365840 is registered in ClinicalTrials.gov with ImmuneOncia Therapeutics Inc. as lead sponsor.

NCT NCT06365840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06365840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR
Lead sponsor
ImmuneOncia Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 13, 2025
Completion date
August 31, 2029
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

histologically or cytologically proven metastatic or locally advanced solid tumors, tmb-h